SPRED1 Activators
SPRED1 activators, as listed, are chemicals that indirectly affect SPRED1 activity by targeting the Ras-ERK signaling pathway or related cellular processes. SPRED1 is a critical regulator of this pathway, and its function is often modulated through changes in the activity of the pathway's components. The chemicals mentioned, such as MEK inhibitors (e.g., PD0325901, Trametinib), EGFR inhibitors (e.g., Erlotinib, Gefitinib), and kinase inhibitors (e.g., Sorafenib, Rapamycin), act on various nodes within the Ras-ERK pathway or intersecting pathways.
These activators are significant in the context of diseases like cancer, where the Ras-ERK pathway often plays a crucial role in tumor growth and survival. By inhibiting components of this pathway, these chemicals can indirectly modulate the effects of SPRED1, thereby affecting cell proliferation and survival. For instance, MEK inhibitors, by blocking downstream signaling, can potentially enhance the regulatory effects of SPRED1 on the pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, another MEK inhibitor, can modulate the pathway where SPRED1 functions, potentially affecting its regulatory role. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Erlotinib, an EGFR inhibitor, indirectly affects the Ras-ERK pathway, which is regulated by SPRED1. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is another EGFR inhibitor that can modulate the signaling pathway involving SPRED1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in several signaling pathways, potentially intersecting with SPRED1's regulatory role. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib inhibits B-Raf, a component of the Ras-ERK pathway, potentially impacting SPRED1's regulatory effects. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, affecting pathways that may cross-talk with the Ras-ERK pathway and SPRED1's function. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 inhibits AKT, a kinase involved in signaling pathways that can interact with the Ras-ERK pathway regulated by SPRED1. | ||||||